Novo Nordisk Diabetes Drug Xultophy Gets Positive CHMP View - Analyst Blog

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Novo Nordisk 's ( NVO ) type II diabetes candidate, Xultophy (IDegLira), received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). Xultophy is a once-daily single injection combination of Novo Nordisk's Tresiba (insulin degludec) and Victoza.

The CHMP recommended the approval of Xultophy for the treatment of adults suffering from type II diabetes in combination with glucose-lowering oral drugs, when such drugs (alone or combined with basal insulin) fail to achieve adequate glycemic control.

A response from the EC is expected by Oct 2014. Novo Nordisk intends to launch Xultophy in Europe in the first half of 2015.

We are encouraged by the CHMP's opinion on Xultophy and believe chances of gaining approval are high. Although the European Commission (EC) is not bound to accept the recommendations of the CHMP, it usually does so.

We note that in two phase III studies (DUAL I and II), patients treated with Xultophy experienced a lower rate of hypoglycemia, compared to Tresiba. The patients also achieved body weight reduction compared to basal insulin treatment.

We remind investors that Novo Nordisk's Victoza 3mg is also under review in the EU for the treatment of adults suffering from obesity and overweight adults with comorbidities such as hypertension, dyslipidemia, sleep apnea or type II diabetes.

Novo Nordisk carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), AbbVie Inc. ( ABBV ) and AstraZeneca plc ( AZN ). While Allergan carries a Zacks Rank #1 (Strong Buy), AbbVie and AstraZeneca hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.